Skip to main content
峆一药业 logo

峆一药业 — Investor Relations & Filings

Ticker · 920478 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2024-11-07 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920478

About 峆一药业

http://www.heryipharma.com/

Anhui Heyi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company focuses on providing high-quality chemical products for various therapeutic areas, including cardiovascular, central nervous system, and anti-infective treatments. With a strong emphasis on technological innovation and quality control, it operates advanced manufacturing facilities that adhere to international standards. Its product portfolio includes key intermediates for widely used medications, supporting both domestic and global pharmaceutical supply chains. The company leverages its expertise in complex chemical synthesis to offer customized solutions and reliable supply to its partners in the life sciences sector.

Recent filings

Filing Released Lang Actions
关于认定核心员工的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Anhui Xuyi Pharmaceutical Co., Ltd. regarding the recognition of core employees. It details the procedures followed, including board and supervisory meetings, public notices, and shareholder approval. The content focuses on personnel recognition rather than financial results, governance structure, or regulatory filings. It does not contain financial data or audit information, nor is it a report or presentation. It is an announcement related to management or board-level decisions about key personnel. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing.
2024-11-07 Chinese
2024年股权激励计划内幕信息知情人买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the company's board regarding the internal investigation and compliance related to the 2024 equity incentive plan. It details the verification of insider trading activities among insiders aware of the plan, referencing regulatory compliance and internal controls. The document does not contain financial statements, earnings data, or detailed financial analysis. It is a regulatory compliance disclosure related to insider trading checks and equity incentive plan confidentiality measures. The document length is short (1068 characters) and it serves as a regulatory announcement rather than a full report or financial filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-11-07 Chinese
上海市锦天城律师事务所关于安徽峆一药业股份有限公司2024年第二次临时股东大会的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the procedural legality and validity of the 2024 second extraordinary general meeting (EGM) of shareholders of Anhui company. It details the convening, attendance, voting procedures, and results of the shareholders meeting. The document does not contain financial statements or management discussion but focuses on the legality and validity of the shareholder meeting and its resolutions. This type of document is a legal proceedings report related to corporate governance and shareholder meetings, not a full annual or interim report, nor a voting results announcement. Therefore, it fits best under Legal Proceedings Report (LTR). The document length is 4242 characters, which is substantive and not a mere announcement or certification, so it is not RPA or RNS.
2024-11-07 Chinese
2024年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2024 second extraordinary general meeting of shareholders of Anhui Xuyi Pharmaceutical Co., Ltd. It includes information about the meeting date, attendance, agenda items, voting results, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on shareholder voting outcomes on various proposals related to the 2024 equity incentive plan and related matters. There are no financial statements or detailed financial performance data presented, nor is this a transcript or presentation. The document is a formal announcement of voting results from a shareholders' meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is sufficient and contains substantive voting details, not just a brief notice or a report publication announcement. Therefore, the appropriate classification is DVA with high confidence.
2024-11-07 Chinese
监事会关于2024年股权激励计划授予激励对象名单的核查意见及公示情况说明
Regulatory Filings Classification · 95% confidence The document is an announcement from a company's supervisory board regarding the verification and approval of the list of incentive recipients under the company's 2024 equity incentive plan. It references relevant laws and regulations, confirms the qualifications and legitimacy of the incentive recipients, and states that no objections were received during the public notice period. The document does not contain financial statements or detailed financial data, nor is it a report or presentation. It is a regulatory announcement related to corporate governance and compliance with equity incentive plan rules. Given the content and length (1647 characters), it fits best as a Regulatory Filing (RNS) rather than a full Management Report or Governance Information report, as it is a formal compliance announcement without detailed governance structure or management discussion. Therefore, the classification is Regulatory Filings (RNS).
2024-10-31 Chinese
监事会关于拟认定核心员工的核查意见
Board/Management Information Classification · 95% confidence The document is an announcement regarding the nomination and recognition of core employees by the company's board and supervisory committee. It includes details about the meeting dates, the nomination process, public disclosure, and confirmation of no objections from employees. There is no financial data, no mention of financial results, no voting results from shareholders, and no regulatory filings or certifications. The content focuses on management decisions about employee recognition, which aligns with internal management or board information. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and does not indicate it is a report or a report announcement, so it is not RPA or RNS.
2024-10-31 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.